EXO Biologics

EXO Biologics is a clinical-stage Belgian biotechnology company transforming the treatment landscape for rare diseases through proprietary exosome-based therapeutics. Founded in 2019 and headquartered in Liège, the company leverages naturally occurring extracellular vesicles (exosomes) as therapeutic messengers—a safer, more consistent, and cost-effective alternative to traditional mesenchymal stem cell therapies. The company's strategic focus addresses therapeutic applications across respiratory diseases, inflammatory bowel diseases, neurology, and oncology, with particular emphasis on severe and rare conditions currently lacking effective treatments. EXO Biologics' lead candidate, EXOB-001, represents a significant regulatory achievement. Derived from human umbilical cord mesenchymal stromal cells, EXOB-001 has secured FDA Rare Pediatric Disease Designation and Orphan Drug Designation, alongside EMA Orphan Drug Designation. In July 2023, the European Medicines Agency approved the EVENEW study—the first regulatory approval for a European clinical trial evaluating MSC-derived exosomes—marking a watershed moment in nanomedicine development. The Phase 1/2 EVENEW trial is assessing EXOB-001's safety and efficacy in preventing severe Bronchopulmonary Dysplasia (BPD), a critical complication affecting preterm newborns without effective preventative therapies. Operationally, EXO Biologics has developed proprietary manufacturing infrastructure through the ExoPulse™ platform, an advanced GMP production system enabling scalable, industrial-grade exosome manufacture. Recognizing market demand for exosome manufacturing capabilities, the company established ExoXpert™—a wholly owned CDMO (Contract Development and Manufacturing Organization) subsidiary launched in January 2024. ExoXpert provides MSC-based exosome manufacturing services to global partners, creating a dual-revenue model while catalyzing ecosystem growth. Keywords: exosomes, extracellular vesicles, nanomedicine, rare disease therapeutics, orphan drug, bronchopulmonary dysplasia, MSC-derived therapies, clinical trials, GMP manufacturing, CDMO, deep tech, regenerative medicine, biopharmaceuticals